AU2017213154B2 - Use of GABAA receptor modulators for treatment of itch - Google Patents

Use of GABAA receptor modulators for treatment of itch Download PDF

Info

Publication number
AU2017213154B2
AU2017213154B2 AU2017213154A AU2017213154A AU2017213154B2 AU 2017213154 B2 AU2017213154 B2 AU 2017213154B2 AU 2017213154 A AU2017213154 A AU 2017213154A AU 2017213154 A AU2017213154 A AU 2017213154A AU 2017213154 B2 AU2017213154 B2 AU 2017213154B2
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
mice
itch
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2017213154A
Other languages
English (en)
Other versions
AU2017213154A1 (en
Inventor
William RALVENIUS
Hanns Ulrich Zeilhofer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of AU2017213154A1 publication Critical patent/AU2017213154A1/en
Application granted granted Critical
Publication of AU2017213154B2 publication Critical patent/AU2017213154B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2017213154A 2016-01-27 2017-01-27 Use of GABAA receptor modulators for treatment of itch Expired - Fee Related AU2017213154B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16153035 2016-01-27
EP16153035.7 2016-01-27
EP16178824.5 2016-07-11
EP16178824 2016-07-11
PCT/EP2017/051866 WO2017129801A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Publications (2)

Publication Number Publication Date
AU2017213154A1 AU2017213154A1 (en) 2018-08-16
AU2017213154B2 true AU2017213154B2 (en) 2023-02-02

Family

ID=57890845

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017213154A Expired - Fee Related AU2017213154B2 (en) 2016-01-27 2017-01-27 Use of GABAA receptor modulators for treatment of itch

Country Status (14)

Country Link
US (3) US10786513B2 (https=)
EP (1) EP3407886A1 (https=)
JP (2) JP7115746B2 (https=)
KR (1) KR102482200B1 (https=)
CN (1) CN108697694B (https=)
AU (1) AU2017213154B2 (https=)
BR (1) BR112018015386A2 (https=)
CA (2) CA3012791C (https=)
CL (1) CL2018002023A1 (https=)
IL (1) IL260775B (https=)
MX (1) MX388862B (https=)
SG (1) SG11201806393QA (https=)
UA (1) UA125463C2 (https=)
WO (1) WO2017129801A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017129801A1 (en) 2016-01-27 2017-08-03 Universität Zürich Use of gabaa receptor modulators for treatment of itch
BR112020021104A2 (pt) * 2018-04-18 2021-02-23 Neurocycle Therapeutics, Inc compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos
WO2019226820A1 (en) 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
BR112021004661A2 (pt) * 2018-09-13 2021-06-01 Saniona A/S composto, composição farmacêutica, método para tratamento de dor neuropática e/ou prurido, e, uso do composto
CA3132810A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of fybromyalgia
CN110004118B (zh) * 2019-03-29 2023-03-28 中国科学院武汉物理与数学研究所 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用
CN120267677A (zh) * 2019-10-23 2025-07-08 纽罗塞克医疗公司 用gabaa受体调节剂的癫痫状况的治疗
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047582A1 (en) * 1999-02-11 2000-08-17 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
US20050245517A1 (en) * 2004-04-29 2005-11-03 Phil Skolnick 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024526A (en) 1911-07-25 1912-04-30 George R Schweikert Chair.
KR20000029548A (ko) 1996-07-25 2000-05-25 더블유. 지. 콜 가바수용체에대한리간드로서의치환된트리아졸로-피리다진유도체
FR2767692B1 (fr) 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
CA2427779A1 (en) 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2004170323A (ja) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
JPWO2005030773A1 (ja) * 2003-09-26 2006-12-07 大日本住友製薬株式会社 新規ピラゾロピリミジン誘導体
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
MX2009001036A (es) 2006-08-04 2009-04-23 Merz Pharma Gmbh & Co Kgaa Pirazolopirimidinas, proceso para su preparacion y su uso como medicina.
RS54510B1 (sr) 2006-11-22 2016-06-30 Incyte Holdings Corporation Imidazotriazini i imidazopirimidini kao inhibitori kinaze
WO2009021957A2 (en) * 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
TWI472529B (zh) 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
JP2012524800A (ja) 2009-04-22 2012-10-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
WO2011011712A1 (en) 2009-07-24 2011-01-27 Concert Pharmaceuticals, Inc. Substituted imidazotriazines
KR20130059400A (ko) 2010-08-25 2013-06-05 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
US20130331394A1 (en) 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia
AU2014219855B2 (en) * 2013-02-19 2017-09-28 Ono Pharmaceutical Co., Ltd. Trk-inhibiting compound
WO2015072853A1 (en) * 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
US10259815B2 (en) 2015-03-20 2019-04-16 Uwm Research Foundation, Inc. Gabaergic ligands and their uses
WO2017129801A1 (en) 2016-01-27 2017-08-03 Universität Zürich Use of gabaa receptor modulators for treatment of itch

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047582A1 (en) * 1999-02-11 2000-08-17 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for gaba receptors
US20050245517A1 (en) * 2004-04-29 2005-11-03 Phil Skolnick 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BESSON M. et al.: PAIN, 2015, vol. 156, no. 3, pages 397 - 404, DOI: 10.1097/01.j.pain.0000460331.33385.e8 *
CARTER R.B. et al.: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1997, vol. 280, no. 3, pages 1284-1295 *
GARCIA DE LUCAS A. et al.: BIOCHEMICAL PHARMACOLOGY, 2014, vol. 93, no. 3, pages 370 - 379, DOI: 10.1016/J.BCP.2014.12.010 *
KOHUT S.J. et al.: PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2008, vol. 90, no. 1, pages 65 - 73, DOI: 10.1016/J.PBB.2008.02.019 *
MUNRO G. et al.: "GABAA receptor modulation: Potential to deliver novel pain medicines?", EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, vol. 716, no. 1, pages 17 - 23, DOI: 10.1016/J.EJPHAR.2013.01.070 *
SAVIC M.M. et al.: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2010, vol. 34, no. 2, pages 376 - 386, DOI: 10.1016/J.PNPBP.2010.01.004 *

Also Published As

Publication number Publication date
AU2017213154A1 (en) 2018-08-16
UA125463C2 (uk) 2022-03-16
US12433898B2 (en) 2025-10-07
JP2022088620A (ja) 2022-06-14
EP3407886A1 (en) 2018-12-05
CN108697694A (zh) 2018-10-23
US20250268912A1 (en) 2025-08-28
RU2018128905A3 (https=) 2020-03-24
CN108697694B (zh) 2022-12-09
US20210100814A1 (en) 2021-04-08
CA3222584A1 (en) 2017-08-03
US11529359B2 (en) 2022-12-20
JP7115746B2 (ja) 2022-08-09
CA3012791C (en) 2024-01-23
US10786513B2 (en) 2020-09-29
CL2018002023A1 (es) 2019-02-01
BR112018015386A2 (pt) 2019-03-19
MX2018009252A (es) 2019-01-21
RU2018128905A (ru) 2020-02-27
JP2019507736A (ja) 2019-03-22
WO2017129801A1 (en) 2017-08-03
US20190134057A1 (en) 2019-05-09
IL260775B (en) 2021-09-30
CA3012791A1 (en) 2017-08-03
KR102482200B1 (ko) 2022-12-27
MX388862B (es) 2025-03-20
SG11201806393QA (en) 2018-08-30
KR20180118623A (ko) 2018-10-31

Similar Documents

Publication Publication Date Title
AU2017213154B2 (en) Use of GABAA receptor modulators for treatment of itch
Ralvenius et al. Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors
Elvin et al. Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation
Soukup et al. The summary on non-reactivation cholinergic properties of oxime reactivators: the interaction with muscarinic and nicotinic receptors
JP6847946B2 (ja) イン・ビボ生着能増強用５−ヒドロキシトリプタミン１ｂ受容体刺激剤
CN111819190A (zh) 器官纤维化的预防和治疗
EP3713644A1 (en) Compositions and methods for modulating hif-2& x391; to improve muscle generation and repair
RU2781636C2 (ru) Применение модуляторов gabaa-рецептора для лечения зуда
BR112019012936A2 (pt) peptídeos d-enanioméricos para a terapia de dor crônica e neuropática
HK1262708A1 (en) Use of gabaa receptor modulators for treatment of itch
EP3856156B1 (en) 5-ht7 antagonist for the treatment of dementia-associated tauopathies
EP3900789A1 (en) Pharmaceutical combination for the treatment of myeloproliferative neoplasms
EP3386510B1 (fr) Derives phosphores pour la prevention ou le traitement des myopathies et traumatismes musculaires
Schweizer Evaluating the potential of TRESK-based gene therapy for the treatment of chronic pain
Fontelonga Development of Small Molecule Therapies Targeting Regeneration for the Treatment of Duchenne Muscular Dystrophy
ES2794323B2 (es) Moxifloxacino para uso en el tratamiento de la atrofia muscular espinal
JP2024542196A (ja) 黄斑変性症を処置するための材料及び方法
WO2025097153A1 (en) Fam222a as a therapeutic target
WO2019088095A1 (ja) 鎮痛剤及びその使用
Adams Co-regulation of GABAA receptors by neurosteroids and protein kinases
Bastakoty Therapeutic inhibition of the Wnt signaling pathway to promote regenerative repair of tissue injury
Amin Epithelial Sodium Channels in the Brain: Effect of High Salt Diet on Their Expression

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee